Skip to main content
Premium Trial:

Request an Annual Quote

The Sad, Strange End of a Legacy

 

After some 40 years with Cold Spring Harbor Laboratory, James Watson retired today. It would've been nice to see this end some other way. But what will always be remembered about his retirement is that it came on the heels of a PR disaster that even the man's Nobel Prize and history of cringe-worthy (but somehow always forgiven) statements couldn't dampen.

In a statement sent from a Gmail account today, Watson announced that he has retired, effective immediately, from his position as chancellor of the Cold Spring Harbor lab. "Closer now to 80 than 79, the passing on of my remaining vestiges of leadership is more than overdue," he writes. He concludes, "I have been much blessed." You can read his full statement here.

There's also a release from Cold Spring Harbor, which you can read here.

 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.